MetaVia (MTVA) Projected to Post Quarterly Earnings on Wednesday

MetaVia (NASDAQ:MTVA) will likely be posting its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect MetaVia to post earnings of ($0.76) per share for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 12:30 PM ET.

MetaVia Trading Down 3.4%

Shares of NASDAQ:MTVA opened at $1.42 on Wednesday. The firm has a 50 day simple moving average of $1.45 and a 200-day simple moving average of $5.06. MetaVia has a twelve month low of $1.17 and a twelve month high of $19.03. The company has a market capitalization of $7.33 million, a PE ratio of -0.17 and a beta of 0.59.

Hedge Funds Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC acquired a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent filing with the SEC. 1.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on MTVA. HC Wainwright reduced their price target on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, March 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a report on Friday, April 24th. Finally, Wall Street Zen upgraded MetaVia from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, MetaVia presently has an average rating of “Hold” and a consensus price target of $26.50.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.